Abstract

In major depressive disorder (MDD), altered gene expression in brain cortex and blood leucocytes may be due to aberrant expression of epigenetic machinery coding genes. Here, we explore the expression of these genes both at the central and peripheral levels. Using real-time quantitative PCR technique, we first measured expression levels of genes encoding DNA and histone modifying enzymes in the dorsolateral prefrontal cortex (DLPFC) and cingulate cortex (CC) of MDD patients (n = 24) and healthy controls (n = 12). For each brain structure, transcripts levels were compared between subject groups. In an exploratory analysis, we then compared the candidate gene expressions between a subgroup of MDD patients with psychotic characteristics (n = 13) and the group of healthy subjects (n = 12). Finally, we compared transcript levels of the candidate genes in blood leucocytes between separate samples of MDD patients (n = 17) and healthy controls (n = 16). In brain and blood leucocytes of MDD patients, we identified an overexpression of genes encoding enzymes which transfer repressive transcriptional marks: HDAC4-5-6-8 and DNMT3B in the DLPFC, HDAC2 in the CC and blood leucocytes. In the DLPFC of patients with psychotic characteristics, two genes (KAT2A and UBE2A) were additionally overexpressed suggesting a shift to a more transcriptionally permissive conformation of chromatin. Aberrant activation of epigenetic repressive systems may be involved in MDD pathogenesis both in brain tissue and blood leucocytes.

Highlights

  • Major depressive disorder (MDD) affects more than 350 million people worldwide and is one of the most common mental illnesses [1]

  • The brain RNAs extracted from postmortem dorsolateral prefrontal cortex (DLPFC-BA 46) and the whole cingulate cortex (CC) have been donated by the Stanley Medical Research Institute brain collection

  • In the DLPFC of MDD patients, we report for the first time the concurrent increase of the steady state mRNA levels of HDAC4-5-6-8 and DNMT3B

Read more

Summary

Introduction

Major depressive disorder (MDD) affects more than 350 million people worldwide and is one of the most common mental illnesses [1]. It is considered as the third leading cause of DALYS (disability-adjusted life years) worldwide and will become the second leading cause of disability by 2030 [2]. MDD is responsible for a dramatic increase in mortality due to suicide, and to somatic diseases (especially metabolic and cardiovascular pathologies) [3]. Increasing knowledge of its basic features represents a major issue, especially because of the suboptimal efficiency of the current treatments

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call